Cullinan Therapeutics, Inc. CGEM Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Regeneron PharmaceuticalsREGN

$266.8M+13.8%

Vor BiopharmaVOR

$2.94M-90.5%

Aclaris TherapeuticsACRS

$1.85M-21.8%

Artiva Biotherapeutics, Inc.ARTV

$9.85M-24.9%

Alumis Inc.ALMS

$35.66M+1,881%

Janux TherapeuticsJANX

$20.99M-5.4%

FAQ

What is Cullinan Therapeutics, Inc.'s operating lease liabilities (total)?

Cullinan Therapeutics, Inc. (CGEM) reported operating lease liabilities (total) of $2.07M in Q2 2026.

How has Cullinan Therapeutics, Inc.'s operating lease liabilities (total) changed year-over-year?

Cullinan Therapeutics, Inc.'s operating lease liabilities (total) increased by 36.3% year-over-year, from $1.52M to $2.07M.

What is the long-term trend for Cullinan Therapeutics, Inc.'s operating lease liabilities (total)?

Over 3 years (2022 to 2025), Cullinan Therapeutics, Inc.'s operating lease liabilities (total) has grown at a -18.8% compound annual growth rate (CAGR), from $5.01M to $2.68M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.